Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 1.40% and Operating profit at -12.80% over the last 5 years
2
Positive results in Mar 26
3
With ROE of 6.39%, it has a fair valuation with a 1.68 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,793 Million (Mid Cap)
25.00
NA
0.79%
-0.29
6.39%
1.62
Revenue and Profits:
Net Sales:
366 Million
(Quarterly Results - Jun 2026)
Net Profit:
114 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.08%
0%
13.08%
6 Months
-6.91%
0%
-6.91%
1 Year
-27.82%
0%
-27.82%
2 Years
21.02%
0%
21.02%
3 Years
-17.86%
0%
-17.86%
4 Years
-41.45%
0%
-41.45%
5 Years
-67.79%
0%
-67.79%
Chengdu Kanghua Biological Products Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.40%
EBIT Growth (5y)
-12.80%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.38
Tax Ratio
15.85%
Dividend Payout Ratio
29.55%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
19.90%
ROE (avg)
16.97%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
1.59
EV to EBIT
18.44
EV to EBITDA
14.56
EV to Capital Employed
1.83
EV to Sales
3.89
PEG Ratio
NA
Dividend Yield
0.80%
ROCE (Latest)
9.95%
ROE (Latest)
6.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
365.90
346.00
5.75%
Operating Profit (PBDIT) excl Other Income
144.90
121.40
19.36%
Interest
0.00
0.90
-100.00%
Exceptional Items
2.70
1.80
50.00%
Consolidate Net Profit
113.80
93.80
21.32%
Operating Profit Margin (Excl OI)
333.90%
290.10%
4.38%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 5.75% vs -18.76% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 21.32% vs -40.29% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,160.70
1,421.60
-18.35%
Operating Profit (PBDIT) excl Other Income
334.30
591.10
-43.44%
Interest
3.70
5.40
-31.48%
Exceptional Items
-3.70
-59.70
93.80%
Consolidate Net Profit
219.90
398.70
-44.85%
Operating Profit Margin (Excl OI)
211.70%
363.30%
-15.16%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -18.35% vs -9.31% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -44.85% vs -21.70% in Dec 2024
About Chengdu Kanghua Biological Products Co., Ltd. 
Chengdu Kanghua Biological Products Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






